Baxter falls after Q2 results miss estimates

Shares of medical device maker Baxter BAX.N down 10.9% at $25 premarket

BAX posts Q2 adj. profit of 54 cents per share, compared with analysts' estimate of 61 cents per share, according to data compiled by LSEG

It reports Q2 sales of $2.81 billion, below estimates of $2.82 billion

Company expects Q3 adj. profit in the range of 58 cents to 62 cents per share, below estimates of 65 cents

Up to last close, stock down 3.8% YTD